TAME Cardiac Arrest

ANZICS CTG Endorsed Study

TAME Cardiac Arrest

Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multi-centre randomised controlled trial

Study Description

The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.

Management Committee

Dr Glenn Eastwood, Dr John Archer, Prof Stephen Bernard, Prof Rinaldo Bellomo, Dr Carol Hodgson, Dr Shay McGuinness, Prof Alistair Nichol, A/Prof Niklas Nielsen, Dr Rachael Parke, Dr Dion Stub, Bridget Ady Kate Ainscough, Anna Hunt

Project Manager

Bridget Ady (TAME Project Manager, ANZIC RC)
Kate Ainscough (TAME Project Manager, ICCTN, Ireland)

Administering Institution

ANZIC-Research Centre, Monash University

Sample Size

1700 patients


National Health & Medical Research Council, Irish Health Research Board, TAME-RENAL, SVAF, New Zealand Health Research Council


CTG1617-001, ACTRN12617000036314, NCT03114033


Glenn Eastwood (email)